The technology is genuinely useful for scientific discovery, but its applications are less dramatic than you might think.

Champions Oncology, Inc.’s CSBR share price has surged by 7.56%, which has investors questioning if this is right time to ...

Survey results revealed a widespread - and often misguided - belief that subcutaneous delivery volumes must be limited to 3 ...

CytomX Therapeutics CTMX, a clinical-stage oncology company, is expected to beat first-quarter 2025 earnings when it reports ...

Precision oncology company Guardant Health has announced a strategic collaboration with Pfizer to support the development and ...

The collaboration reflects Ebn Sina Medical’s commitment to delivering high-quality medicinal products to the local market, ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

Our global Injectables business is delivering a solid revenue performance, driven by each of our three geographies ...

AstraZeneca has started work with tech companies Tempus and Pathos AI on a project that aims to generate a wide-ranging and ...

AstraZeneca, Tempus and Pathos will develop an AI-driven foundational model to develop therapeutics in oncology.

As a stock-picking sector, investors can benefit from deep fundamental research on individual biotech companies ...

Tempus stands to earn $200 million in data licensing and model development fees from the collaborations, the release said.